Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.39 USD
Change Today -0.01 / -2.50%
Volume 626.9K
RXII On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
Frankfurt
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

rxi pharmaceuticals (RXII) Snapshot

Open
$0.40
Previous Close
$0.40
Day High
$0.40
Day Low
$0.38
52 Week High
09/3/14 - $3.98
52 Week Low
05/28/15 - $0.34
Market Cap
25.3M
Average Volume 10 Days
890.2K
EPS TTM
$-0.49
Shares Outstanding
64.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RXI PHARMACEUTICALS (RXII)

Related News

No related news articles were found.

rxi pharmaceuticals (RXII) Related Businessweek News

No Related Businessweek News Found

rxi pharmaceuticals (RXII) Details

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma. The company’s preclinical program includes the development of products for ocular indications with RXI-109, including retinal and corneal scarring. Its discovery stage development programs include a dermatology franchise for the discovery of collagenase and tyrosinase targets for its RNAi platform; and ophthalmology franchise, a program for the discovery of sd-rxRNA compounds for oncology indications, including retinoblastoma. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

15 Employees
Last Reported Date: 05/22/15
Founded in 2011

rxi pharmaceuticals (RXII) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $495.3K
Chief Development Officer
Total Annual Compensation: $413.6K
Compensation as of Fiscal Year 2014.

rxi pharmaceuticals (RXII) Key Developments

RXi Pharmaceuticals Corporation Announces Advancements in its Ophthalmology Clinical Program with RXI-109

RXi Pharmaceuticals Corporation announced that the thirty day review period following the filing of the company's investigational new drug for ocular indications with the U.S. Food and Drug Administration has passed and the IND is now active. As outlined in the company's second quarter earnings call on August 12, 2015, preparations are ongoing for the initiation of a Phase 1/2 trial in Ophthalmology to evaluate the safety and clinical activity of RXI-109 to prevent the progression of the scarring component of retinal diseases. The process to obtain approval from the Investigational Review Board (IRB) is underway. If the current plan is acceptable to the IRB, a multi-dose, dose-escalating trial will initiate early in the fourth quarter of this year. This Phase 1/2 study will be the company's first clinical trial with RXI-109 in Ophthalmology. RXI-109-1501 will focus on patients with advanced age-related macular degeneration or advanced wet AMD. RXI-109 is a self-delivering RNAi compound developed to target connective tissue growth factor (CTGF), a key regulator in scar formation. The goal is to block the formation of sub-retinal scarring that is secondary to the neovascular disease of wet AMD in order to preserve vision for a longer period of time. Currently, there are three ongoing Phase 2a trials evaluating the effect of RXI-109 on scar formation in the skin after surgical revision of hypertrophic scars or keloids. Approximately 100 subjects have been treated with RXI-109 by intradermal injection in all trials to date. RXI-109 has proven to be safe and well tolerated in that target population. The Company expects to provide further updates on its Dermatology and Ophthalmology clinical programs in the coming months.

RXi Pharmaceuticals Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

RXi Pharmaceuticals Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported operating loss of $2,165,000 compared to $2,021,000 a year ago. Net loss was $2,166,000 compared to $2,006,000 a year ago. Net loss applicable to common stockholders was $2,190,000 compared to $3,219,000 a year ago. Basic and diluted loss per share was $0.05 compared to $0.23 a year ago. For the six months, the company reported operating loss of $5,111,000 compared to $4,311,000 a year ago. Net loss was $5,111,000 compared to $4,290,000 a year ago. Net loss applicable to common stockholders was $5,320,000 compared to $7,258,000 a year ago. Basic and diluted loss per share was $0.16 compared to $0.54 a year ago.

RXi Pharmaceuticals Corporation to Report Q2, 2015 Results on Aug 12, 2015

RXi Pharmaceuticals Corporation announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXII:US $0.39 USD -0.01

RXII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RXII.
View Industry Companies
 

Industry Analysis

RXII

Industry Average

Valuation RXII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 276.2x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 187.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RXI PHARMACEUTICALS, please visit www.rxipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.